GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Future Policy Benefits

KYTX (Kyverna Therapeutics) Future Policy Benefits


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.


Kyverna Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.